We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Asterias Biotherapeutics Common Series A | AMEX:AST | AMEX | Ordinary Share |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.945 | 0.00 | 00:00:00 |
As filed with the Securities and Exchange Commission on March 14, 2019
Registration Nos. 333-202674; 333-206237; 333-211995; 333-218951
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO
Form S-8 Registration Statement (No. 333-202674)
Form S-8 Registration Statement (No. 333-206237)
Form S-8 Registration Statement (No. 333-211995)
Form S-8 Registration Statement (No. 333-218951)
UNDER THE SECURITIES ACT OF 1933
Asterias Biotherapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 46-1047971 | |
(State of Incorporation) | (I.R.S. Employer Identification No.) |
6300 Dumbarton Circle
Fremont, California 94555
(510) 456-3800
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
2013 Equity Incentive Plan
(Full titles of the plan)
Brian M. Culley
Chief Executive Officer
Asterias Biotherapeutics, Inc.
6300 Dumbarton Circle
Fremont, California 94555
(Name and Address of Agent for Service)
(510) 456-3800
(Telephone Number, Including Area Code, of Agent For Service)
Copies to:
Tali Sealman, Esq.
Cooley LLP
3175 Hanover Street
Palo Alto, CA 94304
(650) 843-5471
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | ||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | ||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE / DEREGISTRATION OF UNSOLD SECURITIES
On March 8, 2019, pursuant to the Agreement and Plan of Merger, dated November 7, 2018, by and among BioTime, Inc. (“BioTime”), Asterias Biotherapeutics, Inc.(“Asterias”) and Patrick Merger Sub, Inc., a wholly owned subsidiary of BioTime (“Merger Sub”), Merger Sub merged with and into Asterias (the “Merger”), with Asterias surviving the Merger as a wholly owned subsidiary of BioTime.
The Registrant, defined as Asterias, previously registered shares of the Registrant’s Series A Common Stock, $0.001 par value per share, under the below referenced Registration Statements on Form S-8 (the “Registration Statements”) concerning shares issuable or issued under certain employee benefit and equity plans and agreements. As a result of the consummation of the Merger, the Registrant has terminated all offerings of its securities pursuant to the below referenced Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all securities of the Registrant registered pursuant to the Registration Statements that remain unsold as of the date hereof.
Registration No. |
Date
Filed
With the SEC |
Name of Equity Plan |
Number
of Shares of
Common Stock Originally Registered |
||||||
333-202674 | 3/12/2015 | 2013 Equity Incentive Plan | 4,500,000 | ||||||
333-206237 | 8/7/2015 | 2013 Equity Incentive Plan | 3,500,000 | ||||||
333-211995 | 6/13/2016 | 2013 Equity Incentive Plan | 3,000,000 | ||||||
333-218951 | 6/23/2017 | 2013 Equity Incentive Plan | 2,500,000 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, and Rule 478 thereunder, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on this 14 th day of March, 2019.
ASTERIAS BIOTHERAPEUTICS, INC. | ||
By: | /s/ Brian M. Culley | |
Name: | Brian M. Culley | |
Title: | Chief Executive Officer |
1 Year Asterias Biotherapeutics, Inc. Chart |
1 Month Asterias Biotherapeutics, Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions